Stockscreener 앱 받기
1.0043
0.43%
0.0043
60 Degrees Pharmaceuticals Inc 주식(SXTP)의 최신 뉴스
Can 60 Degrees Pharmaceuticals Inc. stock maintain growth trajectoryMarket Trend Review & Daily Stock Momentum Reports - Newser
Is 60 Degrees Pharmaceuticals Inc Equity Warrant a good long term investmentReal-Time Stock Alerts & Rapid Capital Trading Tips - earlytimes.in
Will 60 Degrees Pharmaceuticals Inc. stock deliver long term returnsNew Guidance & Weekly Breakout Opportunity Watchlist - BỘ NỘI VỤ
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Given New $2.80 Price Target at Ascendiant Capital Markets - Defense World
Why 60 Degrees Pharmaceuticals Inc. stock is considered a top pickLayoff News & Smart Swing Trading Alerts - BỘ NỘI VỤ
Dick's Sporting Goods To Rally Around 17%? Here Are 10 Top Analyst Forecasts For Friday - Benzinga
Ascendiant Capital Maintains 60 Degrees Pharmaceuticals (SXTP) Buy Recommendation - Nasdaq
Is 60 Degrees Pharmaceuticals Inc. stock a defensive play in 20252025 Top Gainers & Capital Efficient Trading Techniques - BỘ NỘI VỤ
How 60 Degrees Pharmaceuticals Inc. stock reacts to job market dataMarket Performance Report & Daily Stock Trend Watchlist - BỘ NỘI VỤ
Join 60 Degrees Pharmaceuticals' Exclusive Live Investor Webinar and Q&A Session on October 22 - The Marion Star
Enlivex Therapeutics and 60 Degrees Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Utica Observer Dispatch
60 Degrees Pharmaceuticals Inc. (SXTP) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
60 Degrees Pharma begins enrollment for chronic babesiosis study By Investing.com - Investing.com Nigeria
60 Degrees Pharma begins enrollment for chronic babesiosis study - Investing.com India
60 Degrees Pharmaceuticals announces clinical site now open for patient enrollment - MarketScreener
60 Degrees Pharmaceuticals Launches First-Ever Study for Tafenoquine in Chronic Babesiosis Patients - Quiver Quantitative
60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine - The Manila Times
60 Degrees Pharmaceuticals Announces Clinical Site Now Open - GlobeNewswire
Will 60 Degrees Pharmaceuticals Inc. Equity Warrant stock reach all time highs in 2025 - newser.com
How resilient is 60 Degrees Pharmaceuticals Inc. Equity Warrant stock in market downturnsPortfolio Return Report & Low Volatility Stock Recommendations - newser.com
Is 60 Degrees Pharmaceuticals Inc. stock supported by innovation pipeline2025 Support & Resistance & Growth Focused Stock Pick Reports - newser.com
60 Degrees Pharmaceuticals (NASDAQ:SXTP) Upgraded at Zacks Research - Defense World
How 60 Degrees Pharmaceuticals Inc. Equity Warrant stock performs in high volatility markets2025 Earnings Impact & Risk Controlled Daily Trade Plans - newser.com
Will 60 Degrees Pharmaceuticals Inc. Equity Warrant see short term momentumPortfolio Update Report & High Yield Stock Recommendations - newser.com
Can 60 Degrees Pharmaceuticals Inc. Equity Warrant stock sustain free cash flow growthJuly 2025 Short Interest & AI Enhanced Execution Alerts - newser.com
Is 60 Degrees Pharmaceuticals Inc. stock oversold or undervaluedPortfolio Risk Summary & Safe Capital Allocation Plans - newser.com
Will 60 Degrees Pharmaceuticals Inc. stock attract more institutional investors2025 Volatility Report & Expert Curated Trade Setups - newser.com
What technical charts say about 60 Degrees Pharmaceuticals Inc. Equity Warrant stockWeekly Trade Recap & Weekly Breakout Watchlists - newser.com
Can 60 Degrees Pharmaceuticals Inc. Equity Warrant stock maintain operating margins2025 Trading Volume Trends & Safe Entry Zone Tips - newser.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Fate Therapeutics (FATE), ALX Oncology Holdings (ALXO) and 60 Degrees Pharmaceuticals, Inc. (SXTP) - The Globe and Mail
How to integrate 60 Degrees Pharmaceuticals Inc. Equity Warrant into portfolio analysis toolsSell Signal & AI Enhanced Trade Execution Alerts - newser.com
60 Degrees Pharmaceuticals Faces Financial Challenges Amid Growth Efforts - MSN
0.39%
1.05%
자본화:
|
볼륨(24시간):